Lombardo, Carlo https://orcid.org/0000-0003-4411-1143
Lopez-Ben, Santiago https://orcid.org/0000-0002-5192-9966
Boggi, Ugo https://orcid.org/0000-0002-7505-5896
Gutowski, Piotr
Hrbac, Tomas https://orcid.org/0000-0002-6401-9849
Krska, Lukas
Marquez-Rivas, Javier https://orcid.org/0000-0002-5136-4723
Russello, Domenico https://orcid.org/0000-0001-7757-4334
York, Elisa
Zacharias, Mario
Clinical trials referenced in this document:
Documents that mention this clinical trial
Hemopatch® is effective and safe to use: real-world data from a prospective European registry study
https://doi.org/10.1007/s13304-022-01353-y
Funding for this research was provided by:
Baxter Healtcare SA, Zurich, Switzerland
Università di Pisa
Article History
Received: 29 July 2022
Accepted: 2 August 2022
First Online: 20 August 2022
Declarations
:
: Santiago Lopez-Ben, Lukas Krska, Javier Marquez-Rivas, Domenico Russello, Elisa York, and Mario Zacharias received honoraria from Baxter as advisors for interpreting the raw data and consulting in stratification and interpretation of data in post hoc analyses.
: This registry was conducted in compliance with applicable laws, regulations and guidance. We obtained an independent ethics committee review as well as written and dated approval/favorable opinion from the independent ethics committee (IEC) for the registry protocol/amendment(s). We also obtained written informed consent forms, pediatric assent forms, any consent/assent form updates, patient recruitment procedures (e.g. advertisements), and any written information to be provided to patients with a statement from the IEC that it complies with Good Pharmacoepidemiology Practices requirements and (when applicable) International Conference on Harmonisation Good Clinical Practices. The study was performed in accordance with the tenets of the Declaration of Helsinki.
: All patients provided written informed consent to participate in the study within 72 h post-surgery.
: Not applicable.